Latest News-News-ScinoPharm Taiwan, Ltd.

Mar 2024

ScinoPharm Taiwan Exhibits Steady Operation and Bolsters Development of Injectable Products

ScinoPharm Taiwan (stock code 1789) announced consolidated revenue of NT$3.186 billion, net profit after tax of NT$287 million, and earnings per share (EPS) after tax of NT$0.36.

Oct 2023

ScinoPharm Taiwan obtains Bortezomib for Injection ANDA approval

Bortezomib for Injection developed and produced by ScinoPharm Taiwan, received the U.S. abbreviated new drug application (ANDA) approval on September 26, 2023. This is our first in-house injection product, and the Company has shown the capability of developing and manufacturing injectable products. It is also a milestone for us to strengthen the vertical integration of the Company’s business.

Aug 2023

ScinoPharm Taiwan established a continuous flow R&D laboratory using Corning AFR technology

As one of the top five API manufacturers in Taiwan, ScinoPharm Taiwan recently decided to embrace flow chemistry technology and adopt Corning Advanced Flow-reactor system as a partner. ScinoPharm Taiwan expects to apply Corning AFR to various low-temperature reactions, hydrogenation reactions, and reactions that are difficult to scale up in the traditional batch process.